A PHP Error was encountered
Severity: Warning
Message: fopen(/var/lib/php/sessions/ci_sessionib6nscvocsftc400ic7lj25vs6l3ftnk): Failed to open stream: No space left on device
Filename: drivers/Session_files_driver.php
Line Number: 177
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
A PHP Error was encountered
Severity: Warning
Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)
Filename: Session/Session.php
Line Number: 137
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
Association of sociodemographic and clinical variables with time to start prostate cancer treatment.
Cien Saude Colet
Centro de Ciências da Saúde, Universidade Federal do Espírito Santo. Av. Marechal Campos 1468, Maruípe. 29043-900 Vitória ES Brasil.
Published: September 2019
Introduction: Disparities in prostate cancer care have been evidenced and associated with sociodemographic and clinical factors, which establish the time for diagnosis and initiation of treatment.
Objective: To evaluate the association of sociodemographic and clinical variables with the onset of prostate cancer treatment.
Methods: This is a prospective longitudinal cohort study with secondary data with a population of men with prostate cancer attended in the periods 2010-2011 and 2013-2014 at the Santa Rita de Cássia Hospital in Vitória, Espírito Santo, Brazil.
Results: The study population consisted of 1,388 men. Of the total, those younger than 70 years (OR = 1.85; CI = 1.49-2.31), nonwhite (OR = 1.30; CI = 1.00-1.70), less than 8 years of schooling (OR = 1.52; CI = 1.06-2.17) and referred by the Unified Health System services (OR = 2.52; CI = 1.84-3.46) were more likely to have a delayed treatment. Similarly, the lower the Gleason score (OR = 1.78; CI = 1.37-2.32) and Prostate-Specific Antigens levels (OR = 2.71; CI = 2.07-3.54), the greater the likelihood of delay for the onset of treatment.
Conclusion: Therefore, sociodemographic and clinical characteristics exerted a strong influence on the access to prostate cancer treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/1413-81232018249.31142017 | DOI Listing |
Similar Publications
An MR-only deep learning inference model-based dose estimation algorithm for MR-guided adaptive radiation therapy.
Med Phys
March 2025
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Background: Magnetic resonance-guided adaptive radiation therapy (MRgART) systems combine Magnetic resonance imaging (MRI) technology with linear accelerators (LINAC) to enhance the precision and efficacy of cancer treatment. These systems enable real-time adjustments of treatment plans based on the latest patient anatomy, creating an urgent need for accurate and rapid dose calculation algorithms. Traditional CT-based dose calculations and ray-tracing (RT) processes are time-consuming and may not be feasible for the online adaptive workflow required in MRgART.
View Article and Find Full Text PDFEfficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration-Resistant Prostate Cancer: A Real-World Multi-Intuitional Analysis.
Prostate
March 2025
Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Background: Cabazitaxel (CBZ) is a key drug used for metastatic castration-resistant prostate cancer (mCRPC). However, clinical trial data on CBZ in very elderly patients are still lacking. This study aimed to investigate the efficacy and feasibility of CBZ for mCRPC patients of ≥ 80 years of age.
View Article and Find Full Text PDFDiagnostic image-based treatment planning for online adaptive ultra-hypofractionated prostate cancer radiotherapy with MR-Linac.
J Appl Clin Med Phys
March 2025
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Purpose: A new workflow was investigated for Elekta Unity MR-Linac by removing the computed tomography (CT)-simulation step and using diagnostic CT (DCT) for reference plan generation.
Materials And Methods: Ten patients with ultra-hypofractionated prostate cancer treated with magnetic resonance imaging (MRI)-guided adaptive radiotherapy were retrospectively enrolled. Targets and organs at risk (OARs) were recontoured on DCT, and Hounsfield unit conversions to relative electron density were calibrated for DCT.
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges.
Expert Rev Anticancer Ther
March 2025
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Introduction: Prostate cancer represents a significant oncological challenge, with its natural history predominantly driven by androgen receptor (AR) signaling. The pivotal role of this pathway underscores the rationale for targeting AR activity in therapeutic strategies. However, the development of resistance mechanisms has highlighted the need for advanced therapies to address the complexity of the castration-resistant status.
View Article and Find Full Text PDFPrinciples of optimal multidisciplinary management of prostate cancer in clinical practice.
Cardiooncology
March 2025
Department of Medicine and Population Health Research Institute, McMaster University, Hamilton, Canada.
Advances in the diagnosis and management of prostate cancer have significantly changed the disease landscape. While benefiting from better oncological outcomes, patients are now experiencing higher rates of non-cancer comorbidities, including cardiovascular disease. The increasing impact of cardiovascular disease in those with prostate cancer led to the expanding role of cardio-oncology professionals in enhancing the multidisciplinary care of these patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.